Contribute Try STAT+ Today

Eli Lilly posted earnings Tuesday that surprised and disappointed investors, as both sales and profit figures fell below Wall Street expectations. The company also cut its forecasts for earnings for the year.

The company reported first-quarter sales of $6.81 billion, compared to $7 billion forecast by analysts. Earnings per share excluding one-time items, used by analysts to track business performance, were $1.87, compared to a consensus forecast of $2.12. Earnings this year, the company said, will also be below what analysts expect.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.